Literature DB >> 12497671

Evolution of progestins. Focus on the novel progestin drospirenone.

Ian H Thorneycroft1.   

Abstract

Combination oral contraceptives have changed considerably since they were introduced, in 1960. Although ethinyl estradiol has been the primary estrogen in combination oral contraceptives for years, a number of progestogenic agents have been developed. All of the progestins currently used in combination oral contraceptives are derived from 19-nortestosterone. The exception is a new progestin derived from 17 alpha-spirolactone--drospirenone. As compared with that of other progestins used in combination oral contraceptives, drospirenone pharmacology more closely resembles the pharmacology endogenous progesterone. Its antiandrogenic and antimineralocorticoid activities result in special benefits--e.g., improvement in androgen-related disorders (such as acne and hirsutism) and avoidance of estrogen-related fluid retention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12497671

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  5 in total

1.  Hormonal treatment of acne in women.

Authors:  Tobechi L Ebede; Emily L Arch; Diane Berson
Journal:  J Clin Aesthet Dermatol       Date:  2009-12

Review 2.  Hormonal Contraceptives and Dermatology.

Authors:  Natalie M Williams; Michael Randolph; Ali Rajabi-Estarabadi; Jonette Keri; Antonella Tosti
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

Review 3.  Polycystic ovary syndrome in adolescents: current and future treatment options.

Authors:  George Mastorakos; Irene Lambrinoudaki; George Creatsas
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study.

Authors:  D Romualdi; S De Cicco; M Busacca; D Gagliano; A Lanzone; M Guido
Journal:  J Endocrinol Invest       Date:  2013-09       Impact factor: 4.256

Review 5.  Adult-onset acne: prevalence, impact, and management challenges.

Authors:  Marco A Rocha; Ediléia Bagatin
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.